{{Drugbox
| verifiedrevid = 447986969
| IUPAC_name = trisodium dithiosulphate aurate(I), dihydrate
| image = Na3Au(S2O3)2.png
| image2 = Sodium-gold(I)-thiosulfate-dihydrate-unit-cell-3D-balls.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = [[肌肉注射|肌肉注射]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 15283-45-1
| ATC_prefix = M01
| ATC_suffix = CB02
| PubChem = 170028
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  

<!--Chemical data-->
| chemical_formula =  
| Au=1 | Na=3 | O=6 | S=4
| molecular_weight = 332.08452 g/mol
}}
{{medical}}
'''硫代硫酸金钠'''（{{lang-en|'''Sodium aurothiosulfate'''}}）是[[化學式|化學式]]為Na<sub>3</sub>Au(S<sub>2</sub>O<sub>3</sub>)<sub>2</sub>·2H<sub>2</sub>O的[[無機化合物|無機化合物]]，其陰離子是由一個金原子和二個[[硫代硫酸根|硫代硫酸根]]離子配位而成的直線形離子<ref>{{cite journal | doi = 10.1016/0022-1902(73)80019-3 | title = Crystal and molecular structure of trisodium dithiosulphate aurate(I), dihydrate, Na3[Au(S2O3)2],2H2O | year = 1973 | author = Baggio, R | journal = Journal of Inorganic and Nuclear Chemistry | volume = 35 | pages = 3191 | issue = 9 }}</ref><ref>{{cite journal | doi =  10.1016/S1386-1425(97)83024-7 | title =  Vibrational spectrum of Sanocrysin | year =  1997 | author =  Tobön-Zapata, G | journal =  Spectrochimica Acta Part a Molecular and Biomolecular Spectroscopy | volume =  53 | pages =  183 | issue =  2  }}</ref>。硫代硫酸金钠和其他的金化合物一樣，可以做為{{link-en|抗风湿药|Antirheumatic}}<ref name=shaw>{{cite journal | author=Shaw, III, C. F. | title=Gold-Based Therapeutic Agents| journal=Chemical Reviews | year=1999 | volume=99 | pages=2589–600 | doi=10.1021/cr980431o | pmid=11749494 | issue=9}}</ref>。第一次的[[安慰劑|安慰劑]]對照實驗可能是在1931年開始的，當時用sanocrysin治療[[結核病|結核病]]，以蒸餾水安慰劑比較其效果<ref>Ethical and regulatory aspects of clinical research: readings and commentary, Ezekiel J. Emanuel, Johns Hopkins University Press, 2003, p 140</ref>。

==參考資料==
{{reflist}}

{{金化合物}} 
{{鈉化合物}}

[[Category:硫代硫酸盐|Category:硫代硫酸盐]]
[[Category:一价金化合物|Category:一价金化合物]]
[[Category:钠化合物|Category:钠化合物]]
[[Category:金-硫化合物|Category:金-硫化合物]]
[[Category:疾病調節抗風濕藥物|Category:疾病調節抗風濕藥物]]
[[Category:風濕病學|Category:風濕病學]]
[[Category:金配合物|Category:金配合物]]
{{Pharm-stub}}